In a bid to broaden its neurology franchise, Sunovion Pharmaceuticals, a subsidiary of Sumitomo Dainippon has entered into a global collaboration and license agreement with Otsuka Pharmaceuticals to develop and commercialise four psychiatry and neurology compounds. Both the companies will jointly develop these drugs, and on the commercialisation front, Sumitomo will record sales in Canada, Japan and Asia, while Otsuka will generate sales in forty-one other countries and regions including Europe. The deal aligns with Sumitomo’s growth strategy beyond Latuda, its atypical antipsychotic agent, which is expected to lose US patent exclusivity in 2023.